The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
Open accessAbstract
BACKGROUND: Monogenic IFN-mediated autoinflammatory diseases present in infancy with systemic inflammation, an IFN response gene signature, inflammatory organ damage, and high mortality. We used the JAK inhibitor baricitinib, with IFN-blocking activity in vitro, to ameliorate disease. METHODS: Between October 2011 and February 2017, 10 patients with CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures), 4 patients with SAVI (stimulator of IFN genes-associated [STING-associated] vasculopathy with onset in infancy), and 4 patients with other interferonopathies were enrolled in an expanded access program. The patients underwent dose escalation, and the benefit was assessed by reductions in daily disease symptoms and corticosteroid requirement. Quality of life, organ inflammation, changes in IFN-induced biomarkers, and safety were longitudinally assessed. RESULTS: Eighteen patients were treated for a mean duration of 3.0 years (1.5-4.9 years). The median daily symptom score decreased from 1.3 (interquartile range [IQR], 0.93-1.78) to 0.25 (IQR, 0.1-0.63) (P < 0.0001). In 14 patients receiving corticosteroids at baseline, daily prednisone doses decreased from 0.44 mg/kg/day (IQR, 0.31-1.09) to 0.11 mg/kg/day (IQR, 0.02-0.24) (P < 0.01), and 5 of 10 patients with CANDLE achieved lasting clinical remission. The patients' quality of life and height and bone mineral density Z-scores significantly improved, and their IFN biomarkers decreased. Three patients, two of whom had genetically undefined conditions, discontinued treatment because of lack of efficacy, and one CANDLE patient discontinued treatment because of BK viremia and azotemia. The most common adverse events were upper respiratory infections, gastroenteritis, and BK viruria and viremia. CONCLUSION: Upon baricitinib treatment, clinical manifestations and inflammatory and IFN biomarkers improved in patients with the monogenic interferonopathies CANDLE, SAVI, and other interferonopathies. Monitoring safety and efficacy is important in benefit-risk assessment. TRIAL REGISTRATION: ClinicalTrials.gov NCT01724580 and NCT02974595. FUNDING: This research was supported by the Intramural Research Program of the NIH, NIAID, and NIAMS. Baricitinib was provided by Eli Lilly and Company, which is the sponsor of the expanded access program for this drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
Simple proton spectroscopic imaging.
Dixon, W. T. (1984) · Radiology · doi:10.1148/radiology.153.1.6089263 · Cited by 2,276
JAKS AND STATS: Biological Implications
Leonard, W. J., & O'Shea, J. J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.293 · Cited by 1,804
Activated STING in a Vascular and Pulmonary Syndrome
Liu, Y., Jesus, A. A., Marrero, B., Yang, D., Ramsey, S. E., Montealegre Sanchez, G. A., Tenbrock, K., Wittkowski, H., Jones, O. Y., Kuehn, H. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312625 · Cited by 1,412
Self-citationIdentification of JAK2 as a growth hormone receptor-associated tyrosine kinase
Argetsinger, L. S., Campbell, G. S., Yang, X., Witthuhn, B. A., Silvennoinen, O., Ihle, J. N., & Carter-Su, C. (1993) · Cell · doi:10.1016/0092-8674(93)90415-m · Cited by 974
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Taylor, P. C., Keystone, E. C., van der Heijde, D., Weinblatt, M. E., del Carmen Morales, L., Reyes Gonzaga, J., Yakushin, S., Ishii, T., Emoto, K., Beattie, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608345 · Cited by 872
Self-citationBaricitinib in Patients with Refractory Rheumatoid Arthritis
Genovese, M. C., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., Beattie, S. D., Koch, A. E., Cardillo, T. E., Rooney, T. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507247 · Cited by 627
Self-citationJeremiah, N., Neven, B., Gentili, M., Callebaut, I., Maschalidi, S., Stolzenberg, M.-C., Goudin, N., Frémond, M.-L., Nitschke, P., Molina, T. J., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci79100 · Cited by 562
Gigantism in mice lacking suppressor of cytokine signalling-2
Metcalf, D., Greenhalgh, C. J., Viney, E., Willson, T. A., Starr, R., Nicola, N. A., Hilton, D. J., & Alexander, W. S. (2000) · Nature · doi:10.1038/35016611 · Cited by 491
Fridman, J. S., Scherle, P. A., Collins, R., Burn, T. C., Li, Y., Li, J., Covington, M. B., Thomas, B., Collier, P., Favata, M. F., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902819 · Cited by 463
Rodero, M. P., & Crow, Y. J. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20161596 · Cited by 433
Liu, Y., Ramot, Y., Torrelo, A., Paller, A. S., Si, N., Babay, S., Kim, P. W., Sheikh, A., Lee, C. R., Chen, Y., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33368 · Cited by 406
Self-citationType I interferonopathies: a novel set of inborn errors of immunity
Crow, Y. J. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06220.x · Cited by 404
Epigenetic regulation of macrophage polarization and function
Ivashkiv, L. B. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.11.001 · Cited by 396
Xu, L. L., Warren, M. K., Rose, W. L., Gong, W., & Wang, J. M. (1996) · Journal of Leukocyte Biology · doi:10.1002/jlb.60.3.365 · Cited by 372
THORENS, B. (1987) · Cell · doi:10.1016/0092-8674(87)90245-5 · Cited by 353
Brehm, A., Liu, Y., Sheikh, A., Marrero, B., Omoyinmi, E., Zhou, Q., Montealegre, G., Biancotto, A., Reinhardt, A., Almeida de Jesus, A., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81260 · Cited by 344
Self-citationParsing the interferon transcriptional network and its disease associations
Mostafavi, S., Yoshida, H., Moodley, D., LeBoité, H., Rothamel, K., Raj, T., Ye, C. J., Chevrier, N., Zhang, S.-Y., Feng, T., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.032 · Cited by 337
Agarwal, A. K., Xing, C., DeMartino, G. N., Mizrachi, D., Hernandez, M. D., Sousa, A. B., Martínez de Villarreal, L., dos Santos, H. G., & Garg, A. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.10.031 · Cited by 335
Arima, K., Kinoshita, A., Mishima, H., Kanazawa, N., Kaneko, T., Mizushima, T., Ichinose, K., Nakamura, H., Tsujino, A., Kawakami, A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106015108 · Cited by 327
The Metabolic Syndrome and Concentrations of C-Reactive Protein Among U.S. Youth
Ford, E. S., Ajani, U. A., & Mokdad, A. H. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.878 · Cited by 312
A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans
Kitamura, A., Maekawa, Y., Uehara, H., Izumi, K., Kawachi, I., Nishizawa, M., Toyoshima, Y., Takahashi, H., Standley, D. M., Tanaka, K., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58414 · Cited by 308
Familial chilblain lupus due to a gain-of-function mutation in STING
König, N., Fiehn, C., Wolf, C., Schuster, M., Cura Costa, E., Tüngler, V., Alvarez, H. A., Chara, O., Engel, K., Goldbach-Mansky, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209841 · Cited by 308
Self-citationde Jesus, A. A., Canna, S. W., Liu, Y., & Goldbach-Mansky, R. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112227 · Cited by 282
Self-citationKeystone, E. C., Taylor, P. C., Drescher, E., Schlichting, D. E., Beattie, S. D., Berclaz, P.-Y., Lee, C. H., Fidelus-Gort, R. K., Luchi, M. E., Rooney, T. P., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206478 · Cited by 281
Self-citationFrémond, M.-L., Rodero, M. P., Jeremiah, N., Belot, A., Jeziorski, E., Duffy, D., Bessis, D., Cros, G., Rice, G. I., Charbit, B., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.07.015 · Cited by 235
Melki, I., Rose, Y., Uggenti, C., Van Eyck, L., Frémond, M.-L., Kitabayashi, N., Rice, G. I., Jenkinson, E. M., Boulai, A., Jeremiah, N., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.10.031 · Cited by 203
Development of a Validated Interferon Score Using NanoString Technology
Kim, H., de Jesus, A. A., Brooks, S. R., Liu, Y., Huang, Y., VanTries, R., Montealegre Sanchez, G. A., Rotman, Y., Gadina, M., & Goldbach-Mansky, R. (2018) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2017.0127 · Cited by 190
Self-citationPrevalence and patterns of polyomavirus urinary excretion in immunocompetent adults and children
Polo, C., Pérez, J. L., Mielnichuck, A., Fedele, C. G., Niubo, J., & Tenorio, A. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00882.x · Cited by 168
Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice
Igaz, P., Tóth, S., & Falus, A. (2001) · Inflammation Research · doi:10.1007/pl00000267 · Cited by 152
Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus
Kim, H., Sanchez, G. A. M., & Goldbach‐Mansky, R. T. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1465-5 · Cited by 145
Self-citationKim, H., Brooks, K. M., Tang, C. C., Wakim, P., Blake, M., Brooks, S. R., Sanchez, G. A. M., de Jesus, A. A., Huang, Y., Tsai, W. L., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.936 · Cited by 139
Self-citationOtoda, T., Takamura, T., Misu, H., Ota, T., Murata, S., Hayashi, H., Takayama, H., Kikuchi, A., Kanamori, T., Shima, K. R., et al. (2012) · Diabetes · doi:10.2337/db11-1652 · Cited by 137
Ramesh, V., BERNARDI, B., Stafa, A., Garone, C., Franzonı, E., Abinun, M., Mitchell, P. D., Mitra, D., Friswell, M., Nelson, J. W., et al. (2010) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2010.03727.x · Cited by 120
Mixed Models for Assessing Correlation in the Presence of Replication
Hamlett, A., RYAN, L. M., Serrano-Trespalacios, P., & Wolfinger, R. D. (2003) · Journal of the Air & Waste Management Association · doi:10.1080/10473289.2003.10466174 · Cited by 102
The human polyomavirus BK ( BKP yV): virological background and clinical implications
Rinaldo, C. H., Tylden, G. D., & Sharma, B. N. (2013) · Apmis · doi:10.1111/apm.12134 · Cited by 97
Tanimoto, A., Murata, Y., Wang, K., Tsutsui, M., Kohno, K., & Sasaguri, Y. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m708853200 · Cited by 53
GM-CSF priming of human monocytes is dependent on ERK1/2 activation
Lendemans, S., Rani, M., Selbach, C., Kreuzfelder, E., Schade, F. U., & Flohé, S. (2006) · Journal of Endotoxin Research · doi:10.1177/09680519060120010201 · Cited by 19
Cited by
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
COVID-19: combining antiviral and anti-inflammatory treatments
Stebbing, J., Phelan, A., Griffin, I., Tucker, C., Oechsle, O., Smith, D., & Richardson, P. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30132-8 · Cited by 1,117
Marconi, V. C., Ramanan, A. V., de Bono, S., Kartman, C. E., Krishnan, V., Liao, R., Piruzeli, M. L. B., Goldman, J. D., Alatorre-Alexander, J., de Cassia Pellegrini, R., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00331-3 · Cited by 695
Catanzaro, M., Fagiani, F., Racchi, M., Corsini, E., Govoni, S., & Lanni, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0191-1 · Cited by 605
Metadata
- Authors
- Sanchez, G. A. M., Reinhardt, A., Ramsey, S., Wittkowski, H., Hashkes, P. J., Berkun, Y., Schalm, S., Murias, S., Dare, J. A., Brown, D., Stone, D. L., Gao, L., Klausmeier, T., Foell, D., de Jesus, A. A., Chapelle, D. C., Kim, H., Dill, S., Colbert, R. A., Failla, L., Kost, B., O’Brien, M., Reynolds, J. C., Folio, L. R., Calvo, K. R., Paul, S. M., Weir, N., Brofferio, A., Soldatos, A., Biancotto, A., Cowen, E. W., Digiovanna, J. J., Gadina, M., Lipton, A. J., Hadigan, C., Holland, S. M., Fontana, J., Alawad, A. S., Brown, R. J., Rother, K. I., Heller, T., Brooks, K. M., Kumar, P., Brooks, S. R., Waldman, M., Singh, H. K., Nickeleit, V., Silk, M., Prakash, A., Janes, J. M., Ozen, S., Wakim, P. G., Brogan, P. A., Macias, W. L., & Goldbach-Mansky, R.
- Venue
- Journal of Clinical Investigation
- Published
- 2018-06-11
- Volume
- 128
- Issue
- 7
- Pages
- 3041-3052
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2796581040
- Cited by
- 536
- References
- 38
- FWCI
- 23.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.